Improving gastrointestinal cancer therapy by uniting stakeholders

Area of Science:

• Oncology
• Gastroenterology
• Translational Medicine

Background:

• Gastrointestinal (GI) cancers have low survival rates, necessitating improved treatment strategies.
• Precision oncology, utilizing molecular diagnostics and biomarkers, offers personalized treatment for GI cancer patients.
• Current adoption of advanced molecular profiling in GI cancer management needs enhancement.

Purpose of the Study:

• To report on the first Translational and Precision GI-Oncology-Bench to Bedside Meeting.
• To foster collaboration among scientists, clinicians, and industry professionals in GI oncology.
• To discuss strategies for improving the translation of basic science discoveries into clinical practice for GI cancers.

Main Methods:

• A 3-day meeting was held from April 23-28, 2023, in Freiburg, Germany.
• The meeting convened 120 participants from science, clinical practice, and industry.
• Key topics included bedside applications, data analysis, biomarkers, novel technologies, and therapeutics.

Main Results:

• The meeting facilitated idea exchange on advancing precision oncology in GI cancer care.
• Discussions focused on bridging the gap between research and clinical application.
• Forty-seven presentations covered diverse aspects of GI cancer translational research.

Conclusions:

• Enhanced coordination among scientists, clinicians, and industry is essential for advancing precision GI oncology.
• Translating basic science findings into clinical practice is key to improving patient outcomes.
• The meeting highlighted the importance of collaborative efforts in developing and implementing novel GI cancer treatments.